Switch from Antagonist to Agonist of the Androgen Receptor Bicalutamide is Associated with Prostate Tumour Progression in a New Model System
Overview
Authors
Affiliations
Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androgen ablation therapy. Androgen-sensitive LNCaP cells were kept in androgen-depleted medium for 87 passages. The new LNCaP cell subline established in this manner, LNCaP-abl, displayed a hypersensitive biphasic proliferative response to androgen until passage 75. Maximal proliferation of LNCaP-abl cells was achieved at 0.001 nM of the synthetic androgen methyltrienolone (R1881), whereas 0.01 nM of this compound induced the same effect in parental cells. At later passages (> 75), androgen exerted an inhibitory effect on growth of LNCaP-abl cells. The non-steroidal anti-androgen bicalutamide stimulated proliferation of LNCaP-abl cells. AR protein expression in LNCaP-abl cells increased approximately fourfold. The basal AR transcriptional activity was 30-fold higher in LNCaP-abl than in LNCaP cells. R1881 stimulated reporter gene activity in LNCaP-abl cells even at 0.01 nM, whereas 0.1 nM of R1881 was needed for induction of the same level of reporter gene activity in LNCaP cells. Bicalutamide that acts as a pure antagonist in parental LNCaP cells showed agonistic effects on AR transactivation activity in LNCaP-abl cells and was not able to block the effects of androgen in these cells. The non-steroidal AR blocker hydroxyflutamide exerted stimulatory effects on AR activity in both LNCaP and LNCaP-abl cells; however, the induction of reporter gene activity by hydroxyflutamide was 2.4- to 4-fold higher in the LNCaP-abl subline. The changes in AR activity were associated neither with a new alteration in AR cDNA sequence nor with amplification of the AR gene. Growth of LNCaP-abl xenografts in nude mice was stimulated by bicalutamide and repressed by testosterone. In conclusion, our results show for the first time that the nonsteroidal anti-androgen bicalutamide acquires agonistic properties during long-term androgen ablation. These findings may have repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention.
Azam H, Veale C, Zitzmann K, Marcone S, Gallagher W, Prencipe M PLoS One. 2024; 19(12):e0309491.
PMID: 39671399 PMC: 11642960. DOI: 10.1371/journal.pone.0309491.
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.
Dotto G, Buckinx A, Ozdemir B, Simon C Nat Rev Cancer. 2024; 25(2):93-108.
PMID: 39587300 DOI: 10.1038/s41568-024-00772-w.
Hypoxic Signaling Is Modulated by Calcium Channel, CaV1.3, in Androgen-Resistant Prostate Cancer.
OReilly D, Buchanan P Bioelectricity. 2024; 4(2):81-91.
PMID: 39350777 PMC: 11441368. DOI: 10.1089/bioe.2022.0007.
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.
Venkadakrishnan V, Presser A, Singh R, Booker M, Traphagen N, Weng K Nat Commun. 2024; 15(1):6779.
PMID: 39117665 PMC: 11310309. DOI: 10.1038/s41467-024-51156-5.
Cacciatore A, Shinde D, Musumeci C, Sandrini G, Guarrera L, Albino D Nat Commun. 2024; 15(1):6672.
PMID: 39107274 PMC: 11303763. DOI: 10.1038/s41467-024-50908-7.